Cited by 200Endometriosis Research and TreatmentUterine Myomas and TreatmentsMenstrual Health and Disorders

Adenomyosis incidence, prevalence and treatment: United States population-based study 2006–2015

Open access
Yu, Onchee, Schulze-Rath, Renate, Grafton, Jane, Hansen, Kelly, Scholes, Delia, Reed, Susan D.·2020·American Journal of Obstetrics and Gynecology

Abstract

Background Adenomyosis symptoms are disabling. Population-based data on incidence and prevalence of adenomyosis are lacking that could guide future evidence-based treatments and clinical management.Objective To evaluate the incidence, 10-year secular trends, and prevalence of adenomyosis diagnoses and to describe symptoms and treatment patterns in a large U.S. cohort.Study design We performed a retrospective population-based cohort study of women aged 16-60 years in 2006-2015, enrolled in Kaiser Permanente Washington, a mixed-model health insurance and care delivery system. Adenomyosis diagnoses identified by ICD codes from the International Classification of Diseases 9th and 10th editions and potential covariates were extracted from computerized databases. Women with prior hysterectomy, and for incidence estimates women with prior adenomyosis diagnoses, were excluded. Linear trends in incidence rates over the 10-year study period were evaluated using Poisson regression. Rates and trend tests were examined for all women adjusting for age using direct standardization to the 2015 study population, by age groups, and by race/ethnicity. Chart reviews were performed to validate diagnostic accuracy of ICD codes in identifying adenomyosis incidence. Symptoms and treatment patterns at diagnosis and in the following 5 years were assessed.Results A total of 333,693 women contributed 1,185,855 woman-years (2006-2015) for incidence calculations. Associated symptom-related codes (menorrhagia or abnormal uterine bleeding, dysmenorrhea or pelvic pain, dyspareunia, and infertility) were observed in 90.8%; 18.0% had co-occurrent endometriosis codes and 47.6% had co-occurrent uterine fibroid codes. The overall adenomyosis incidence was 1.03% or 28.9 per 10,000 woman-years, with a high of 30.6 in 2007 and a low of 24.4 in 2014. Overall age-adjusted estimated incidence rates declined during the 10-year study interval (linear trend P < .05). Incidence was highest for women aged 41-45 years (69.1 per 10,000 woman-years in 2008) and was higher for black (highest 44.6 per 10,000 woman-years in 2011) vs white women (highest 27.9 per 10,000 woman-years in 2010). Overall prevalence in 2015 was 0.8% and was highest among women aged 41-45 years (1.5%). Among the 624 potential adenomyosis cases identified by diagnostic codes in 2012-2015 and with sufficient information in the medical record to determine true case status, 490 were confirmed as incident cases, yielding a 78.5% (95% confidence interval, 75.1%, 81.7%) positive predictive value of adenomyosis ICD-9/ICD-10 codes for identifying an incident adenomyosis case. Health care burden was substantial: 82.0% of women had hysterectomies, nearly 70% had imaging studies suggestive of adenomyosis, and 37.6% used chronic pain medications.Conclusion Adenomyosis burden to the individual and the health care system is high. Incidence rates are disproportionately high among black women. These findings are of concern, as currently available long-term medical therapies remain limited beyond hysterectomy. Our data and methodologies are novel and could serve as a foundation to guide clinicians and health care systems to develop clinical management plans and track outcomes for women with adenomyosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajog.2020.01.016

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The rate of concurrent pelvic endometriosis and/or adenomyosis in this CSE cohort (45.1%) is higher than that reported in the general population.

    “This rate of our result is higher than that reported for pelvic endometriosis and adenomyosis in the general population23,24 and may be correlated.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 4

  1. Donnez J, Donnez O, Dolmans MM. Intro- duction: uterine adenomyosis, another enig- matic disease of our time. Fertil Steril 2018;109(3):369-70.
  2. Van den Bosch T, Van Schoubroeck D. Ul- trasound diagnosis of endometriosis and ade- nomyosis: state of the art. Best Pract Res Clin Obstet Gynaecol 2018;51:16-24.
  3. Vercellini P, Parazzini F, Oldani S, Panazza S, Bramante T, Crosignani PG. Adenomyosis at hysterectomy: a study on frequesncy distribu- tion and patient characteristics. Hum Reprod 1995;10(5):1160-2.
  4. Parazzini F, Verecellini P, Panazza S, Chatenout L, Olidani S, Crosignani PG. Risk factors for adenoymosis. Hum Reprod 1997;12(6):1275-9.

Cited by

Sorted by citations

Authors
Yu, O., Schulze-Rath, R., Grafton, J., Hansen, K., Scholes, D., & Reed, S. D.
Affiliations
  • Kaiser Permanente Washington Health Research Institute (US)
  • University of Washington (US)
Corresponding author
Reed, Susan D.
Venue
American Journal of Obstetrics and Gynecology
Publisher
Elsevier BV
Published
2020-07
Volume
223
Issue
1
Pages
94.e1-94.e10
ISSN
0002-9378 (ISSN-L)
OpenAlex
W2999448645
Cited by
200
References
23
Citations by year
2026: 30 · 2025: 33 · 2024: 30 · 2023: 35 · 2022: 36 · 2021: 28 · 2020: 8
FWCI
23.56
Type
journal article
Language
en
Open access
Locations
  • American Journal of Obstetrics and Gynecology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Bayer AG
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Health Sciences › Medicine › Obstetrics and Gynecology › Uterine Myomas and Treatments
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Menstrual Health and Disorders
Keywords
adenomyosis, incidence, prevalence, secular trends, dysmenorrhea, menorrhagia, dyspareunia, infertility, endometriosis, uterine fibroids, hysterectomy, hysterectomy rates, hysterectomy indications, hysterectomy complications, medical treatment, treatment patterns, Kaiser Permanente Washington, women
MeSH terms
Adolescent, Adult, Female, Humans, Middle Aged, Retrospective Studies, Time Factors, United States, Cohort Studies, Incidence, Prevalence, Young Adult, Adenomyosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review